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Abstract
Thinking about public health impact should inform HIV curative investigations. Should an effective HIV cure or sustained
viral remission intervention emerge from ongoing investigations, implementation strategies aimed at ensuring global access
will be needed if these approaches are to be impactful, and planning accordingly makes sense now. Specifically, we discuss
three key access barriers to future cure-related interventions: high cost of the strategy; non-financial challenges to
procurement, distribution and point-of-care delivery; and non-adherence and the need for long-term monitoring. As we
argue, plans and decision-making for overcoming each of these barriers will need to be developed in advance. An evaluation
of remaining barriers and likely global impact of the leading strategies under investigation should inform decisions on
which strategy might receive funding priority. Among the strategies being investigated, implementation barriers for
latency-reversing agents, immunotherapy and combination antiretroviral therapy (ART) may be overcome on a global
scale with some effort. Overcoming implementation barriers for medically complex and high-risk interventions, such as
stem cell and, to some degree, gene therapy, may be less feasible.
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Introduction
The US National Institutes of Health and the International AIDS
Society (IAS) both prioritise research toward a cure for HIV [1].
A sterilising cure or sustainable remission would address health
complications associated with long-term ART, such as renal and
central nervous system toxicity [2,3], as well as expensive
and burdensome life-long daily treatment, challenges of
adherence, and related potential for infectiousness and for drug
resistance [1].
Two broad cure-related outcomes are being pursued: a sterilising
cure and controlled remission. The former is generally defined as
the complete eradication of all replication-competent HIV [4]; the
latter, as durable control of persistent infection in the absence
of daily ART [4]. Potential cure-related interventions include stem
cell transplantation and perhaps a ‘shock and kill’ strategy (using
agents that reverse latency and eliminate all virus-producing cells).
Potential remission interventions include very early ART and
immunotherapy. This perspective article will assume that a
successful intervention in either broad outcome category will: (1)
be administered for a finite period of time (a combination dose
at one time or at different times for a fixed time period); (2) work
in some individuals who have accessed ART and have an
undetectable viral load; (3) have acceptable toxicity and efficacy
that is comparable to ART; and (4) require long-term monitoring
for late rebound in HIV replication [5].
We lay out three potential barriers to global access to such
interventions, if and when proven safe and efficacious: (1) high
cost of the relevant cure-related strategy; (2) non-financial
challenges to its smooth procurement, distribution and point-of-
care delivery; and (3) non-adherence. These are not the only
barriers but they struck us as among the foremost barriers to rollout
of a cure intervention. We also suggest ways to overcome each
barrier and argue that institutional stakeholders would need to
explore how a simple, effective and sustainable delivery for future
HIV cure-related interventions could emerge. We argue that one
measure for greater future access is priority funding for
interventions likely to become scalable. Finally, we address possible
objections.
Potential access barriers to future cure-related
interventions
In 2016, only 53% of people living with HIV globally were
accessing antiretroviral treatment [6]. While future HIV cure-related
interventions could boost access, for example, by facilitating
adherence [5], three potential barriers may delay global scale-up
of these future interventions:
(1) High cost: Like many patented, novel health technologies,
future HIV cure-related interventions will probably be costly
immediately following regulatory approval. In some low- and
middle-income countries (LMIC), first-line antiretroviral regimens
cost up to US$ 23,000 per person per year when initially developed
[7]. While there are no reliable estimates of the cost of cure-related
strategies, estimates for autologous cell transplantation and gene
therapy for other indications range from US$75,000–150,000 [8,
9]. The cost of manufacturing broadly neutralising antibodies for
immunotherapy will probably remain very high, even years after
approval [10]. Additional costs in any HIV cure-related intervention
will come from care delivery and follow-up care to rule out viral
recrudescence.
(2) Non-financial challenges to procurement, distribution and
point-of-care delivery: Bureaucratic challenges and regulatory
policies could also delay procurement and distribution of HIV
cure-related interventions. Chronic shortages in public budgets,
and supply chain challenges such as inconsistent transportation
and storage, could delay distribution of cure-related interventions,
primarily in LMIC [11], although these shortages are by no means
absent in richer countries. Notably, these same limitations apply
to standard ART regimens.
Health-care worker shortages and inadequate laboratory facilities
could also hinder delivery of any intervention, particularly biologic
interventions that are medically complex and currently require
highly skilled health professionals, advanced medical equipment
and a dependable power supply. For example, apheresis
procedures, which are needed for cell isolation from blood, are
medically and technically challenging [12]. In West Africa, for
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example, as of 2014, Nigeria was the only West African country
with the capacity to use apheresis procedures for platelet
collection [12].
(3) Non-adherence: While one advantage of cure-related
interventions is reduction in the burden of daily medication intake,
adherence challenges remain. Combination treatment or multiple-
dose regimens may threaten adherence and follow-up in resource-
limited settings, where individuals are unable to pay for frequent
transportation to treatment centres and face multiple additional
structural and further challenges to adherence [13]. For all
interventions, adherence to ongoing evaluations to detect viral
recrudescence (especially crucial in sustainable remission
interventions) may prove not only challenging but expensive to
secure [5]. The very fact that interventions permit a break in daily
adherence to oral medications – in some ways an answer to ART
adherence challenges – may create loss to follow-up, another
adherence hazard [14]. Finally, during the treatment interruptions,
nonadherence to safer sex practices may present a major ethical
challenge – the risk of onward transmission to sexual partners and
to fetuses.
Ensuring equitable access to future cure-related
interventions
To mitigate potential barriers to global scale-up of future HIV
cure-related interventions, the following should be considered:
(1) High cost of HIV cure-related strategy
First, national and global policy-makers would need to discuss the
supply of future HIV cure-related interventions. For example, by
augmenting models that worked for the global rollout of ART, the
delay from regulatory approval to access in many LMICs could be
reduced. When antiretroviral drugs were initially priced, some
countries issued TRIPS (Trade-Related Aspects of Intellectual
Property Rights) Agreement compulsory licences, which allowed
them to produce or import generic versions at significantly reduced
prices [15]. Countries with high HIV burden could similarly seek
an initial agreement with global policy-makers to issue compulsory
licences that enable immediate access to cure-related drugs.
Alternatively, in return for guaranteed low prices for future HIV
cure-related drugs, global policy-makers could extend patents for
drug manufacturers’ other blockbuster and ‘lifestyle’ drugs, or
establish a pay-for-performance ‘Health Impact Fund’ [16] that
may give pharmaceutical companies the option of selling their
drugs at a uniformly low price globally, while being rewarded for
the global health impact of their efforts. Global health impact can
be measured in terms of impact on the HIV-related global burden
of disease [17].
(2) Non-financial challenges to procurement, distribution and
point-of-care delivery
A procurement agency for HIV cure-related interventions could
be established in advance of drug approval. Stakeholders in HIV
cure-related research and care – people living with HIV, other
activists, researchers, pharmaceutical companies, funding agencies
and governments – would need to be engaged in discussions of
the logistical, structural and cultural challenges facing
implementation [18]. Governments in HIV-endemic LMICs could
review past health-care interventions whose implementation has
been challenging (e.g., scaling up the use of ART) and collaborate
with implementation experts to preempt similar challenges. For
example, they could work with the U.S. President‘s Emergency
Fund for AIDS Relief (PEPFAR) to strengthen supply chains
and set aside resources for training health-care workers and
laboratory technicians to administer cure-related interventions.
However, with recent proposed cuts in PEPFAR budget, there
would be fewer available resources to support early implementation
planning [19].
Non-financial procurement, distribution and delivery barriers are
more resolvable for medications that can be easily distributed and
administered in resource-limited settings, such as the short-course
oral or injectable medication that is expected in most latency-
reversing treatment and immunotherapy, if successful. Even here,
however, added challenges pertain to management of viral
recrudescence. It would be harder to implement medically complex
interventions such as stem cell therapy and, to a lesser degree,
gene therapy in remote locations, including many where ART is
readily available.
(3) Non-adherence
Non-adherence challenges are likely to be worse, or at least
different, for some potential cure-related interventions than for
others. A one-time HIV sterilising cure intervention, administered
by highly skilled staff in a single visit, with little or no follow-up,
would be ideal from the point of view of adherence, although this
is unlikely to be achievable. Spaced out remission interventions,
such as a single injection every few months or years, are also
appealing, but if non-adherence to the schedule risks failure and
viral recrudescence, then the public health benefit of the curative
regimen as compared to standard ART will be questioned.
Adherence strategies used with the scale-up of ART in developing
countries [20] could be enhanced and replicated for a short-course
HIV cure-related intervention such as latency-reversing agents and
immunotherapy. Some challenges to remission strategies would
need to be explored further, even before approval. For example,
would short message service (SMS) reminders for follow-up viral
load evaluation be more, or less, effective than regular SMS
reminders to take oral ART [21]? Stem cell transplantation requires
prolonged immunosuppressant use and close follow-up, which
would make adherence difficult in the general population. In
principle, monitoring could help improve adherence even in the
absence of self-motivation. In practice, however, it is hard to
accomplish and user motivation is essential.
Prioritising interventions most likely to ensure
equitable access
For future HIV cure-related strategies, likelihood of effectiveness
could be hampered not only by failure to address the barriers listed
above, but also by barriers which the above solutions are unlikely
to overcome, even with substantial resources and sustained efforts.
Based on recent modeling work, an antiretroviral-free viral
suppression intervention would be cost-effective in a sub-Saharan
African country if it costs less than US$1400 [5] or less than
US$2000 [22]. Currently, excessive costs and other acute barriers
are relatively likely to be removable for latency-reversing agents,
immunotherapy and intensive ART-based sustainable remission for
the reasons stated above. If proven safe and efficacious, and with
efforts to address barriers, these interventions currently seem most
promising to make the greatest impact on the global HIV epidemic.
Stem cell therapy, and perhaps gene therapy, will probably have
the least impact on the global epidemic, even if proven safe and
efficacious and given similar efforts. The main reason is the
formidable implementation barriers to their successful procurement,
distribution and delivery.
Scalability is among the reasons why there is increasing interest
in developing interventions for sustainable virologic remission [23].
In general, directing more resources to studying cure-related
interventions most likely to be globally impactful would increase
expected impact and global equity. Such priority should not be
absolute, and can take the form of added ‘points’ in funders’
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calculations for relatively scalable strategies, where other ‘points’
are given for success in preclinical studies [24], innovation and
other desiderata.
These funding priorities would also help keep HIV cure-related
studies fair to study subjects. Many early phase cure-related trials
are risky for participants, compared to the alternative of remaining
stable on ART [22,25] – a major ethical challenge [26]. The primary
justification of the social resources and risk to participants in all
clinical studies comes from social value, primarily in terms of
potential for substantial medical effects [27]. In this context, that
means a substantial decrease in the global HIV burden [28]. While
general contribution to human knowledge is also valuable, when
the resources and opportunity cost are high, as are risks to
individuals (such as in many cure studies, which are both risky
and prioritised over other important investigations into infectious
disease), especially high social value is needed for justification,
and the surest way to achieve this is through the potential for
high public health impact.
Possible objections
This call for early action on these matters could meet with three
objections. First, we may be many years away from an approved
HIV cure-related strategy. Before any intervention is approved,
access barriers may wane without the need for special efforts, or
specific efforts may become ineffective. By analogy, ART prices
dropped dramatically in the late 1990s and early 2000s, by about
98% within a few years [29]. At the same time, one might add,
removing implementation barriers is expensive for LMICs, and
worth undertaking only once a specific cure-related intervention
is already known to be safe and efficacious – not now.
However, some access barriers may take years to resolve, as the
histories of negotiating price reduction at the global level and
strengthening health-care systems clearly illustrate. With nearly
37 million people currently living with HIV worldwide, and about
17 million of them without access to ART [6], every year of delay
in global rollout of approved HIV cure-related interventions would
contribute substantially to the number of AIDS-related deaths,
complications and new transmissions. In addition, eliminating
implementation barriers through strengthening health-care
systems, procurement and delivery, results in improvement of other
health outcomes not limited to the HIV field. These additional
benefits may even be realised before an HIV cure-related
intervention is ready for rollout.
Finally, one might argue that even non-scalable HIV cure-related
interventions may inspire scalable ones, or still other medical
breakthroughs. This is not a wholly fanciful assumption for stem
cell and gene therapy where, for instance, advances in scalability
could be expected over the coming few decades [30]. However,
in a time of financial crunch [19], it is hard to justify allocating
substantial financial resources to research that lacks potential major
global impact [28].
Conclusions
This perspective article describes three access barriers to successful
rollout of future HIV cure-related interventions globally. It
recommends measures to overcome these barriers, and thereby
facilitate equitable access to these interventions. In particular, we
have stressed that strategies and infrastructure used to expand
ART access could also help resolve some of these implementation
barriers. Planning and decision-making on drug prices, personnel
training and short-term research priorities during the early phases
of HIV cure-related research would also be advisable. A recently
proposed decrease in US HIV/AIDS funding [19] may undermine
this advance planning.
Even if the recommended measures are taken in earnest, removing
implementation barriers will be challenging. Relatively medically
complex and high-risk interventions like stem cell therapy and,
to a lesser degree, gene therapy would be especially difficult to
fully scale up globally, best efforts notwithstanding. Combination
ART regimens, latency-reversing agents and immunotherapy, if
proven safe and efficacious, are more likely to produce a scalable
cure-related strategy.
Although not discussed in this perspective article, certain
population groups, such as pregnant women and children,
may face additional access barriers. For example, there is a
lag time of 8 to 10 years for the development of optimal
pediatric formulations of HIV treatment [31]. Technical
complexity and a small, fragmented pediatric market are barriers
to developing these formulations [31]. We expect that a scalable
HIV cure-related strategy will require even more advance planning
for attaining optimal pediatric formulations that are scalable
globally.
The IAS has published a Global Scientific Strategy towards an HIV
cure, tasked to coordinate global efforts in developing and rolling
out HIV cure-related interventions that are safe, affordable and
scalable [1]. A similar policy strategy document would be needed
on how to build an effective and sustainable delivery system for
future cure-related interventions. Such a document would render
any intervention ultimately developed for HIV cure or sustained
remission more likely to make a major impact on the global HIV
epidemic.
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